These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12134369)

  • 1. Positron emission tomography in thyroid cancer management.
    Larson SM; Robbins R
    Semin Roentgenol; 2002 Apr; 37(2):169-74. PubMed ID: 12134369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation.
    van Tol KM; Jager PL; Piers DA; Pruim J; de Vries EG; Dullaart RP; Links TP
    Thyroid; 2002 May; 12(5):381-7. PubMed ID: 12097198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography.
    Jadvar H; McDougall IR; Segall GM
    Nucl Med Commun; 1998 Jun; 19(6):547-54. PubMed ID: 10234658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
    Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
    Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports.
    Huang TS; Chieng PU; Chang CC; Yen RF
    J Endocrinol Invest; 1998 Jun; 21(6):392-8. PubMed ID: 9699132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET and alternative imaging in the management of thyroid carcinoma.
    Al-Nahhas AM
    Nucl Med Rev Cent East Eur; 2003; 6(2):139-45. PubMed ID: 14737730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
    Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
    Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
    Ranade R; Kand P; Basu S
    Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
    Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
    Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
    Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
    J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer.
    McDougall IR; Davidson J; Segall GM
    Nucl Med Commun; 2001 May; 22(5):485-92. PubMed ID: 11388568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer.
    Seiboth L; Van Nostrand D; Wartofsky L; Ousman Y; Jonklaas J; Butler C; Atkins F; Burman K
    Thyroid; 2008 Feb; 18(2):103-11. PubMed ID: 18279011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive lymph node metastases found by (18)F-FDG-PET/CT in a patient with diffuse sclerosing variant of papillary thyroid carcinoma.
    Xu YH; Song HJ; Qiu ZL; Luo QY
    Hell J Nucl Med; 2011; 14(2):188-9. PubMed ID: 21761030
    [No Abstract]   [Full Text] [Related]  

  • 20. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.